急性髓系白血病 (AML) 的治疗格局正在迅速变化。许多新药物和低强度治疗方案已获得批准，血液学家和肿瘤学家可以在学术和社区环境中安全使用。美国食品和药物管理局 (FDA) 于 2022 年 11 月在社区举办了关于 AML 治疗的虚拟研讨会。 FDA 的几位成员以及学术和社区环境中的执业血液学家和肿瘤学家参加了研讨会。研讨会的目的是讨论社区肿瘤学环境中治疗 AML 患者的挑战和机遇。这里总结了这些讨论和关键考虑因素。© 作者 2024。由牛津大学出版社出版。这项工作的要素是由美国联邦政府的雇员编写的。

The treatment landscape for acute myeloid leukemia (AML) is rapidly changing. Many new agents and lower-intensity regimens have been approved and can be safely used by hematologists and oncologists in both academic and community settings. The US Food and Drug Administration (FDA) held a virtual symposium on AML treatment in the community in November 2022. Several members of the FDA, along with practicing hematologists and oncologists in both academic and community settings, participated in the symposium. The goal of the symposium was to discuss challenges and opportunities in the treatment of patients with AML in community oncology settings. A summary of these discussions and key considerations are presented here.© The Author(s) 2024. Published by Oxford University Press. Elements of this work have been written by employees of the US Federal Government.